These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 22075751)

  • 1. The effect of CYP7A1 polymorphisms on lipid responses to fenofibrate.
    Shen J; Arnett DK; Parnell LD; Lai CQ; Straka RJ; Hopkins PN; An P; Feitosa MF; Ordovás JM
    J Cardiovasc Pharmacol; 2012 Mar; 59(3):254-9. PubMed ID: 22075751
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association of common C-reactive protein (CRP) gene polymorphisms with baseline plasma CRP levels and fenofibrate response: the GOLDN study.
    Shen J; Arnett DK; Parnell LD; Peacock JM; Lai CQ; Hixson JE; Tsai MY; Province MA; Straka RJ; Ordovas JM
    Diabetes Care; 2008 May; 31(5):910-5. PubMed ID: 18285551
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fenofibrate effect on triglyceride and postprandial response of apolipoprotein A5 variants: the GOLDN study.
    Lai CQ; Arnett DK; Corella D; Straka RJ; Tsai MY; Peacock JM; Adiconis X; Parnell LD; Hixson JE; Province MA; Ordovas JM
    Arterioscler Thromb Vasc Biol; 2007 Jun; 27(6):1417-25. PubMed ID: 17431185
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High-Molecular-Weight β-Glucan Decreases Serum Cholesterol Differentially Based on the CYP7A1 rs3808607 Polymorphism in Mildly Hypercholesterolemic Adults.
    Wang Y; Harding SV; Eck P; Thandapilly SJ; Gamel TH; Abdel-Aal el-SM; Crow GH; Tosh SM; Jones PJ; Ames NP
    J Nutr; 2016 Apr; 146(4):720-7. PubMed ID: 26936139
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of micronized fenofibrate on plasma lipoprotein levels and hemostatic parameters of hypertriglyceridemic patients with low levels of high-density lipoprotein cholesterol in the fed and fasted state.
    Genest J; Nguyen NH; Theroux P; Davignon J; Cohn JS
    J Cardiovasc Pharmacol; 2000 Jan; 35(1):164-72. PubMed ID: 10630748
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacogenetic association of the APOA1/C3/A4/A5 gene cluster and lipid responses to fenofibrate: the genetics of lipid-lowering drugs and diet network study.
    Liu Y; Ordovas JM; Gao G; Province M; Straka RJ; Tsai MY; Lai CQ; Zhang K; Borecki I; Hixson JE; Allison DB; Arnett DK
    Pharmacogenet Genomics; 2009 Feb; 19(2):161-9. PubMed ID: 19057464
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of fenofibrate therapy on paraoxonase1 status in patients with low HDL-C levels.
    Phuntuwate W; Suthisisang C; Koanantakul B; Chaloeiphap P; Mackness B; Mackness M
    Atherosclerosis; 2008 Jan; 196(1):122-128. PubMed ID: 17412348
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of Cytochrome P450 7A1 (CYP7A1) Polymorphism on Lipid Responses to Simvastatin Treatment.
    Liu N; Yang G; Liu Y; Hu M; Cai Y; Hu Z; Jia C; Zhang M
    J Cardiovasc Pharmacol; 2020 Feb; 75(2):168-173. PubMed ID: 31663874
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rare PPARA variants and extreme response to fenofibrate in the Genetics of Lipid-Lowering Drugs and Diet Network Study.
    Irvin MR; Zhang Q; Kabagambe EK; Perry RT; Straka RJ; Tiwari HK; Borecki IB; Shimmin LC; Stuart C; Zhong Y; Hixson JE; Arnett DK
    Pharmacogenet Genomics; 2012 May; 22(5):367-72. PubMed ID: 22336959
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Response to micronized fenofibrate treatment is associated with the peroxisome-proliferator-activated receptors alpha G/C intron7 polymorphism in subjects with type 2 diabetes.
    Foucher C; Rattier S; Flavell DM; Talmud PJ; Humphries SE; Kastelein JJ; Ayyobi A; Pimstone S; Frohlich J; Ansquer JC; Steiner G;
    Pharmacogenetics; 2004 Dec; 14(12):823-9. PubMed ID: 15608561
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The genetic architecture of fasting plasma triglyceride response to fenofibrate treatment.
    Smith JA; Arnett DK; Kelly RJ; Ordovas JM; Sun YV; Hopkins PN; Hixson JE; Straka RJ; Peacock JM; Kardia SL
    Eur J Hum Genet; 2008 May; 16(5):603-13. PubMed ID: 18212815
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of common variants of ABCB1 and CYP7A1 genes in serum lipid levels and lipid-lowering efficacy of statin treatment: a meta-analysis.
    Li Q; Hong J; Wu J; Huang ZX; Li QJ; Yin RX; Lin QZ; Wang F
    J Clin Lipidol; 2014; 8(6):618-629. PubMed ID: 25499945
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Common variants of HMGCR, CETP, APOAI, ABCB1, CYP3A4, and CYP7A1 genes as predictors of lipid-lowering response to atorvastatin therapy.
    Poduri A; Khullar M; Bahl A; Sehrawat BS; Sharma Y; Talwar KK
    DNA Cell Biol; 2010 Oct; 29(10):629-37. PubMed ID: 20578904
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differential effects of fenofibrate and extended-release niacin on high-density lipoprotein particle size distribution and cholesterol efflux capacity in dyslipidemic patients.
    Franceschini G; Favari E; Calabresi L; Simonelli S; Bondioli A; Adorni MP; Zimetti F; Gomaraschi M; Coutant K; Rossomanno S; Niesor EJ; Bernini F; Benghozi R
    J Clin Lipidol; 2013; 7(5):414-22. PubMed ID: 24079282
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genome-wide association study indicates variants associated with insulin signaling and inflammation mediate lipoprotein responses to fenofibrate.
    Frazier-Wood AC; Aslibekyan S; Borecki IB; Hopkins PN; Lai CQ; Ordovas JM; Straka RJ; Tiwari HK; Arnett DK
    Pharmacogenet Genomics; 2012 Oct; 22(10):750-7. PubMed ID: 22890011
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of fenofibrate therapy and ABCA1 polymorphisms on high-density lipoprotein subclasses in the Genetics of Lipid Lowering Drugs and Diet Network.
    Tsai MY; Ordovas JM; Li N; Straka RJ; Hanson NQ; Arends VL; Arnett D
    Mol Genet Metab; 2010 Jun; 100(2):118-22. PubMed ID: 20346718
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Variants identified in a GWAS meta-analysis for blood lipids are associated with the lipid response to fenofibrate.
    Aslibekyan S; Goodarzi MO; Frazier-Wood AC; Yan X; Irvin MR; Kim E; Tiwari HK; Guo X; Straka RJ; Taylor KD; Tsai MY; Hopkins PN; Korenman SG; Borecki IB; Chen YD; Ordovas JM; Rotter JI; Arnett DK
    PLoS One; 2012; 7(10):e48663. PubMed ID: 23119086
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interactions between CYP7A1 A-204C and ABCG8 C1199A polymorphisms on lipid lowering with atorvastatin.
    Wei KK; Zhang LR; Zhang Y; Hu XJ
    J Clin Pharm Ther; 2011 Dec; 36(6):725-33. PubMed ID: 21128988
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Paradoxical effects of fenofibrate and nicotinic acid in apo E-deficient mice.
    Declercq V; Yeganeh B; Moshtaghi-Kashanian GR; Khademi H; Bahadori B; Moghadasian MH
    J Cardiovasc Pharmacol; 2005 Jul; 46(1):18-24. PubMed ID: 15965350
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The influence of fenofibrate on lipid profile, endothelial dysfunction, and inflammatory markers in type 2 diabetes mellitus patients with typical and mixed dyslipidemia.
    Ghani RA; Bin Yaakob I; Wahab NA; Zainudin S; Mustafa N; Sukor N; Wan Mohamud WN; Kadir KA; Kamaruddin NA
    J Clin Lipidol; 2013; 7(5):446-53. PubMed ID: 24079286
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.